FDA Clearance Tracker · P160030-S010
Freestyle Libre Flash Glucose Monitoring System; FreeStyle Libre 14 Day Flash Glucose Monitoring System
Last checked: Nov 20, 2026Latest source record: Oct 31, 2018 (this decision)Source: openFDAMethods & limitations
Decided
Oct 31, 2018
Approved
Time to decision
247 days
Received Feb 26, 2018. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P160030-S010
- Device name
- Freestyle Libre Flash Glucose Monitoring System; FreeStyle Libre 14 Day Flash Glucose Monitoring System
- Applicant
- Abbott Diabetes Care, Inc.
- Applicant location
- Alameda, CA
- Received
- Feb 26, 2018
- Decided
- Oct 31, 2018
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P160030
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for the addition of the FreeStyle LibreLink App (iOS) as a compatible reading device and alternative primary display for the FreeStyle Libre and Freestyle Libre 14 Day Systems.
Source documents
Other decisions for Abbott Diabetes Care, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K233537 · Decided Apr 23, 2024 · 172 days after receipt
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.